Sequentially-targeted biomimetic nano drug system for triple-negative breast cancer ablation and lung metastasis inhibition
Jialong Fan,Bin Liu,Ying Long,Zhou Wang,Chunyi Tong,Wei Wang,Peidong You,Xuanming Liu
DOI: https://doi.org/10.1016/j.actbio.2020.06.025
IF: 10.633
2020-09-01
Acta Biomaterialia
Abstract:<p>As a breast cancer subtype with high mortality in women, the efficient treatment of Triple-negative breast cancer (TNBC) is still a challenge due to its unique metastatic mode and poor prognosis. In this study, we developed a biomimetic nanodrug system (denoted as NPs) based on erythrocyte membrane (M)-camouflaged graphene oxide quantum dots (GOQDs, G) for TNBC therapy. The TAT (T) and RGD (R) peptides were used to endow targeting accumulation ability of Gamabufotalin (CS-6, C) and doxorubicin (DOX, D) in tumor tissue. <em>In vitro</em> assay indicated good biocompatibility, prolonged blood circulation time (3-fold longer than GT NPs), and effectively enhanced cell and nucleus targeting capability of this nanosystem. Fluorescence activated cell sorter (FACS) analysis indicated that the combination of DOX and CS-6 induced TNBC cell apoptosis more than 89 % under the ratio of 10:1. <em>In vivo</em> assay indicated that the accumulation of NPs in tumor sites increased about 2-fold compared to naked GTDC NPs, which was accompanied by high tumor apoptosis rates through blocking chemotherapy-activated cyclooxygenase-2 (COX-2) and enhancing DOX's anti-tumor activity of chemical drugs (85 %). Moreover, comparing with the control, the average number of lung metastatic nodules in tumor-bearing mice reduced 84 %, the molecular mechanism of which is related to the down expression of COX-2, matrix metalloproteinase 9 (MMP9) and vascular endothelial growth factor (VEGF). Taken together, our results proved that the developed NPs can inhibit the growth and suppress metastasis of TNBC, which broaden our insights into the application of CS-based strategy for efficient TNBC therapy.</p>
engineering, biomedical,materials science, biomaterials